Novo Nordisk Lowers Forecast Amid Wegovy, Ozempic Slump

On this episode of Stock Movers:
- Vestas Wind Systems jumped after the Danish wind developer said it is launching a new share buyback program of as much as €150 million ($172 million).
- Siemens Healthineers expects the impact from tariffs to roughly double to €400 million ($460 million) in fiscal 2026, according to Chief Financial Officer Jochen Schmitz.
- Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new chief executive.

See omnystudio.com/listener for privacy information.